This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Small-Cap Winners & Losers

Small-cap stocks largely slung under the major indices Wednesday, and one of the worst-performing names was XTL Biopharmaceuticals (XTLB - Get Report).

The Valley Cottage, N.Y., firm plunged 17.2% to $2.92 on news it had suspended development on its XTL-2125 compound, a proposed treatment for hepatitis C, after an early-phase study yielded statistically insignificant results in drug efficacy.

Angeion (ANGN), which makes noninvasive cardio-respiratory diagnostic systems, forecast reduced profitability for the fiscal third and fourth quarters vs. last year due to dwindling revenue from its largest clinical-research customer. Despite positive results for the most recent quarter, shares of the St. Paul, Minn., company lost 13.1%, or $1.42, to $9.42.

Meanwhile Georgia-based Matria Healthcare (MATR - Get Report) said it will end its short-lived relationship with insurer Wellmark Blue Cross & Blue Shield at year-end. The collaboration, which began in only February, had been originally slated to last for 10 years. Shares slid 6.3% to $29.42.

Matria helped take down with it both the Russell 2000 and the S&P SmallCap 600, which respectively gave up 0.9% and 1.1%.

Apparel maker Oxford Industries (OXM - Get Report), also a member of both indices, sank 3.5% to $42.66 after cutting its outlook for the fiscal fourth quarter and full year. Adjusted earnings for the quarter, now predicted at 96 cents to $1.01 a share, would miss Thomson Financial's estimates by at least 2 cents. Prior guidance had called for $1 to $1.07 a share.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
INO $8.11 -1.90%
IVAN $0.26 9.52%
MATR $7.24 -0.14%
OXM $75.75 -1.50%
STAR $13.47 -0.74%


DOW 17,887.49 -40.71 -0.23%
S&P 500 2,083.84 -5.62 -0.27%
NASDAQ 4,925.5940 -13.7330 -0.28%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs